Korea's Celltrion blueprints $514M biologics plant in China, beefing up biosimilar, contract manufacturing

Amber Tong

The Chinese city of Wuhan might have sprung to worldwide infamy for the coronavirus outbreak originating from one of its seafood markets, but if Celltrion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Korea's Celltrion blueprints $514M biologics plant in China, beefing up biosimilar, contract manufacturing

Amber Tong

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

New fund will pressure flailing biotechs, as investor frustration boils over

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

Caribou lays off 32% of staff, cuts lupus cell therapy program before first patient

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Ko­re­a's Cell­tri­on blue­prints $514M bi­o­log­ics plant in Chi­na, beef­ing up biosim­i­lar, con­tract man­u­fac­tur­ing

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

Korea's Celltrion blueprints $514M biologics plant in China, beefing up biosimilar, contract manufacturing